Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial will address the gap in published data on the effect of dolutegravir (DTG)-associated drug-resistant mutations on viral suppression among people remaining on DTG-based antiretroviral therapy. It will also address the gap in the optimal management strategy for this population.
Phase:
PHASE3
Details
Lead Sponsor:
University of Nairobi
Collaborators:
Instituto Nacional de Sade, Mozambique London School of Hygiene and Tropical Medicine Muhimbili University of Health and Allied Sciences SolidarMed